Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Hybio Pharmaceutical, Dr. Reddy’s Forge Peptide API Partnership

Fineline Cube Dec 29, 2025
Company Deals

Shionogi Acquires RADICAVA ALS Business for $2.5 Billion from Tanabe Pharma

Fineline Cube Dec 23, 2025
Company Deals

Coherent Biopharma Licenses PDC CBP-1018 to MultiValent in $2 Billion Prostate Cancer Deal

Fineline Cube Dec 23, 2025
Company Deals

MiniMed Diabetes Files for IPO, Seeking Nasdaq Listing as MMED

Fineline Cube Dec 22, 2025
Company Deals

Simcere Zaiming Licenses ADC SIM0613 to Ipsen in $1.06 Billion Deal

Fineline Cube Dec 22, 2025
Company Policy / Regulatory

NDRC Expands Foreign Investment in Healthcare with 2025 Catalogue

Fineline Cube Dec 29, 2025
Company Drug

AstraZeneca and Ionis’ Eplontersen Wins China Approval for ATTRv-PN as First Gene-Silencing Therapy

Fineline Cube Dec 29, 2025
Company Drug

AstraZeneca Secures NMPA Approval for Fasenra in EGPA, Demonstrating Superior Steroid-Sparing Effect

Fineline Cube Dec 29, 2025
Company Medical Device

Microport EP Medtech’s Pressure Monitoring Catheter Approved by NMPA

Fineline Cube Dec 5, 2022

Shanghai Microport EP Medtech Co., Ltd’s disposable pressure monitoring magnetic positioning radiofrequency catheter has been...

Company Drug

Henlius Biotech Doses First Patient in Phase I Study for HLX60 in China

Fineline Cube Dec 5, 2022

Shanghai Henlius Biotech Inc. (HKG: 2696) announced the first patient dosing of a Phase I...

Company Drug

Fudan Team Presents Ribociclib Phase II Bridging Study Results at ESMO Asia

Fineline Cube Dec 5, 2022

A Fudan University Shanghai Cancer Center team led by Shao Zhimin made an oral presentation...

Company Drug

Hansoh’s EGFR Inhibitor Ameile Filed for EMA Review by Partner EQRx

Fineline Cube Dec 5, 2022

China-based Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) announced that a market filing for its...

Company Drug

Sinocelltech’s SCTV01C Vaccine Included in China’s Emergency Use Program

Fineline Cube Dec 5, 2022

China-based Sinocelltech Group Ltd (SHA: 688520) announced the inclusion of its recombinant novel coronavirus alpha+beta...

Company Drug

Lynk Pharmaceuticals Doses First Patient in Phase II Study for LNK01003

Fineline Cube Dec 5, 2022

China-based Lynk Pharmaceuticals (Hangzhou) Co., Ltd announced first patient dosing in a Phase II clinical...

Company Deals

Lavamed Secures USD 40M in Angel and Series A Financing Rounds

Fineline Cube Dec 5, 2022

Lavamed, a high-end neurointervention device maker based in Suzhou, has successively closed angel and Series...

Company Drug

Innovent Biologics Doses First Volunteer in Orismilast Phase I Study

Fineline Cube Dec 5, 2022

China-based Innovent Biologics Inc., (HKG: 1801) and Denmark-based partner Union Therapeutics A/S revealed that a...

Company Drug

Daiichi Sankyo Doses First Patient in Global Phase III TROPION-Lung08 Study

Fineline Cube Dec 5, 2022

Japan-based Daiichi Sankyo Inc. (TYO: 4568) announced the first patient dosed in the global multi-center...

Company Deals

Tsingke Biotech Secures RMB 400M Series B Financing for Expansion

Fineline Cube Dec 5, 2022

Beijing Tsingke Biotech Co., Ltd. a gene synthesis company based in Beijing, reportedly raised RMB...

Company Deals

China Medical System Licenses Opzelura from Incyte for Greater China and Southeast Asia

Fineline Cube Dec 5, 2022

China Medical System Holdings (CMS; HKG: 0867) announced the establishment of a licensing agreement with...

Company Deals

SAFE Raises RMB 500M in Series D Financing to Expand CRO Services

Fineline Cube Dec 5, 2022

Serve Accurate Faithful Evaluation (SAFE), a contract research organization (CRO) co-founded by the Chinese Academy...

Company Medical Device

Peijia Medical Enrolls First Patient in GeminiOne TEER System Study

Fineline Cube Dec 5, 2022

China’s Peijia Medical Ltd (HKG: 9996) announced first patient enrollment in a multi-center clinical study...

Company Drug

NMPA Approves Henlius’ HLX04 Biosimilar for Lung and Colorectal Cancer

Fineline Cube Dec 2, 2022

The National Medical Products Administration (NMPA) website indicates that China-based Shanghai Henlius Biotech’s (HKG: 2696)...

Company Deals

Yifan Pharma Transfers F-627 Distribution Rights in Germany to Apogepha

Fineline Cube Dec 2, 2022

China-based Yifan Pharmaceutical Co., Ltd (SHE: 002019) announced the transfer of exclusive distribution rights in...

Company Drug

Pyxis Oncology Receives FDA Approval for Biosion’s PYX-106 Clinical Trials

Fineline Cube Dec 2, 2022

China-based Biosion, Inc’s US partner Pyxis Oncology, Inc. (NASDAQ: PYXS) announced receiving clinical trial approval...

Company Deals

Eli Lilly Ends License for Innovent’s Tyvyt Outside China

Fineline Cube Dec 2, 2022

Eli Lilly & Co’s (NYSE: LLY) Q3 2022 SEC filing released last month revealed that...

Company Deals

Novartis Partners with Sinopharm for Commercial Promotion of Gleevec and Exjade in China

Fineline Cube Dec 2, 2022

Swiss giant Novartis (NYSE: NVS) entered into a promotion agreement with China-based Sinopharm Group Co.,...

Company Deals Digital

Luye Pharma Partners with Nhwa and Fine Hin to Commercialize Toludesvenlafaxine

Fineline Cube Dec 2, 2022

China-based Luye Pharma Group (HKG: 2186), Jiangsu Nhwa Pharmaceutical Co., Ltd (SHE: 002262), and Beijing...

Company Deals

Pediatrix Therapeutics Licenses Tris Pharma’s ADHD Portfolio for Greater China

Fineline Cube Dec 2, 2022

China-based Pediatrix Therapeutics announced a licensing agreement with US firm Tris Pharma, Inc., obtaining exclusive...

Posts pagination

1 … 527 528 529 … 601

Recent updates

  • AstraZeneca and Ionis’ Eplontersen Wins China Approval for ATTRv-PN as First Gene-Silencing Therapy
  • AstraZeneca Secures NMPA Approval for Fasenra in EGPA, Demonstrating Superior Steroid-Sparing Effect
  • Innovent Biologics Secures NMPA Approval for TABOSUN as First Neoadjuvant Dual‑IO Therapy for MSI‑H/dMMR Colon Cancer
  • Wantai Biological Secures NMPA Approval for First Oral HIV Self-Test Kit in China
  • Allist Pharmaceuticals Secures Breakthrough Therapy Designation for Furmonertinib in EGFR PACC‑Mutated NSCLC
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

AstraZeneca and Ionis’ Eplontersen Wins China Approval for ATTRv-PN as First Gene-Silencing Therapy

Company Drug

AstraZeneca Secures NMPA Approval for Fasenra in EGPA, Demonstrating Superior Steroid-Sparing Effect

Company Drug

Innovent Biologics Secures NMPA Approval for TABOSUN as First Neoadjuvant Dual‑IO Therapy for MSI‑H/dMMR Colon Cancer

Company Medical Device

Wantai Biological Secures NMPA Approval for First Oral HIV Self-Test Kit in China

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.